AGP Executive Report
Last update: 4 hours agoObesity drug deal: Novo Nordisk agreed to pay up to US$2.6 billion to China’s Hengrui Pharma for rights to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist in Phase 1, with an upfront US$300 million and milestones/royalties; Novo gets exclusive global rights except mainland China, Hong Kong, Macao and Taiwan. Muscle-sparing weight loss: Regeneron reported new Phase 2 COURAGE results showing trevogrumab can prevent lean mass and muscle loss during GLP-1 (semaglutide)-induced weight loss, with findings presented at EASD and set for publication in The Lancet. Food safety alert in Macao: The Municipal Affairs Bureau ordered a recall and sales stop for a “Familie” black truffle sauce after tests found excessive total arsenic (0.60 mg/kg), urging residents to stop eating the affected batch. Local healthcare access: Macao Union Medical Center announced holiday service changes for National Day (Oct 1–2), with most outpatient services closed but emergencies/inpatients/hemodialysis continuing. Heat relief services: Hong Kong’s Home Affairs Department opened 19 community heat shelters with enhanced cooling, water access and support for vulnerable groups while a Very Hot Weather Warning is in force. Hospital milestone: Macao’s Hospital Authority held a flag-raising ceremony for the 77th PRC anniversary, marking staff pride and national planning priorities.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
